Apple commits $500M to U.S.-based rare earth recycling firm MP Materials
The tech giant announced on Tuesday that with this deal, it's committed to buying American-made rare earth magnets developed at MP Materials' flagship facility in Fort Worth, Texas. The factory will develop a series of neodymium magnet manufacturing lines specifically designed for Apple products.
Apple says that once the American-made magnets are built, they will be shipped across the country and all over the world to help address increasing global demand for the material.
The two companies will also collaborate to establish a rare earth recycling line in Mountain Pass, California. The facility will allow MP Materials to process recycled rare earth feedstock, including materials from used electronics and post-industrial scrap, and reuse it in Apple products.
In addition, the companies will work together to develop novel magnet materials and processing technologies to enhance magnet performance.
Apple says the commitment announced on Tuesday is part of its pledge to spend more than $500 billion in the U.S. over the next four years.
The tech giant first used recycled rare earth elements in the Taptic Engine of iPhone 11 in 2019. Today, almost all magnets across its devices are made with 100 percent recycled rare earth elements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Texas Card House Celebrates 10 Years of Poker and Second Season of Trailblazer
AUSTIN, Texas, July 16, 2025--(BUSINESS WIRE)--Texas Card House first opened its doors 10 years ago in Austin, Texas. The private poker club became the first of its kind. Since then, the company has grown into a leading chain of entertainment venues, setting a new standard for the poker experience. With six locations operating 24/7 across Texas, Texas Card House has built a strong reputation among players of all levels. Each venue offers unique features and promotions designed to appeal to everyone—from casual and beginner players to seasoned professionals. The Social locations in Austin and Las Colinas elevate the experience even further, offering full-service fine dining that enhances every visit. Private rooms and full-floor rental options make Texas Card House an exceptional choice for corporate events, bachelor parties, and group outings. The success of their inaugural proprietary tournament, Trailblazer, underscores the brand's expertise and commitment to delivering top-tier poker experiences. The tournament was a resounding success. The tournament tour made stops at all 6 locations giving out $7 million along the way. There were over 18,000 entries and high stakes games every day for the chance to win $1 million and a Chevy Trailblazer SUV at the final table. Texas Card House has just announced the second season of the Trailblazer Tournament tour along with the dates of each stop. There is already a lot of buzz and anticipation not only across Texas but around the world. The excitement is palpable as TCH ambassadors, including last season's winner Mallory Klaus, represented Texas Card House at the World Series of Poker in Las Vegas. As updates and information about the second season of the Trailblazer Tournament tour are released, Texas Card House will continue to captivate new audiences and further establish its reputation. For more information on events, promotions, and poker offerings, visit About Texas Card House: Texas Card Houses are the premier poker destinations of Texas. Featuring up to 70 poker tables, craft cocktails, an upscale atmosphere, and full-service restaurants at their Social locations. Texas card house provides an exceptional environment for all levels of players and invites you to experience a new level of excitement and entertainment View source version on Contacts Media Contact:Herbert MatteiEmail: herbert@ Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards
Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting obligations and listing standards. Share trading will move to the OTC Expert Market temporarily, with potential to uplist to OTCQB as soon as SEC filings are current, with plan to return to Nasdaq or to NYSE American. SANTA ANA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, today announced that it has raised $2 million in new capital from a Japanese strategic investor, who will help NKGen bring its novel NK cell therapy, troculeucel, autologous expanded NK cell therapy, to the Japanese market. The new investment was made in the form of shares of the Company's common stock priced at $0.25 per share and warrants, as described in the Company's Form 8-K filed with the Securities and Exchange Commission on July 16, 2025. This new injection of capital, the Company's ramping up of its Phase 2 clinical trial, the expected near-term satisfaction of public company reporting requirements and satisfaction of the previously disclosed payment obligation on the Company's senior secured debt are all critical to position the Company for long-term success. 'This past year presented significant external challenges, particularly stemming from the unexpected bankruptcy of our former parent company, NKMax Co., Ltd. in June 2024,' said Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen. 'This event initially disrupted our ability to raise capital in the U.S. despite the encouraging progress we continued to make in our clinical trials and compassionate use cases. However, our team remained focused and committed to our mission. Through disciplined execution of our science and clinical programs, we not only sustained our momentum but also succeeded in securing the capital necessary to acquire a majority stake in NKMax out of bankruptcy, as previously disclosed. This transaction, expected to officially close in the coming month, removes a major overhang and allows us to consolidate key intellectual property rights across Asia. This strategic acquisition has already sparked renewed interest from both U.S. and international investors. We look forward to sharing further details in the near future about NKMax and strategic relationships and plans in Asia.' 'This marks our first strategic investor in an important market for our therapy for Alzheimer's and other neurodegenerative diseases,' said James Graf, NKGen's Interim Chief Financial Officer. 'As in our other recently announcing funding, this new funding comes at a pivotal time for the Company, which has faced operational challenges due to limited financial resources and the need to make hard decisions on our use of cash, including the unfortunate but unavoidable delay in our financial filings. With all the necessary service providers fully engaged on the effort now, we're on track to regain compliance in the near term.' Mr. Graf continued, 'The Company has been informed by the OTC Markets Group that its trading will move from OTC Pink to the Expert Market until it regains compliance in its financial filings. The Expert Market allows for limited trading but does not allow public access to bid and ask prices or other information, including trading volume. Instead, pricing information will only be accessible to brokers and market makers. The move will make it more difficult for investors to freely trade the shares of NKGen during this short period until we regain filing compliance. We take our filing obligations seriously and greatly regret the short-term impact resulting from our prior limited access to capital. We ask our investors for patience during this time, after which we expect to emerge on OTCQB and later back on Nasdaq well-positioned for the future.' The Company also announced that it is committed to uplisting back to Nasdaq or to NYSE American as soon as it meets the requirements for newly listed companies, including among other things SEC filing compliance, minimum market capitalization and public float and minimum share price. On February 25, 2025, the Company's shareholders approved a reverse split that is intended to aid in compliance with the share price requirement before uplisting, if so exercised. About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contact: Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
TSMC quarterly profit seen hitting record but Trump tariffs, forex a concern
TAIPEI (Reuters) -TSMC, the world's main producer of advanced AI chips, is expected to post a 52% jump in second-quarter profit to record levels on Thursday, though U.S. tariffs and a strong Taiwan dollar could weigh on its outlook. Taiwan Semiconductor Manufacturing Co, the world's largest contract chipmaker and a key supplier to Nvidia and Apple, is forecast to report net profit of T$377.4 billion ($12.9 billion) for the three months through June 30, according to an LSEG SmartEstimate compiled from 21 analysts. SmartEstimates place greater weight on forecasts from analysts who are more consistently accurate. The company will report the headline profit figure at 0530 GMT which will be followed by an earnings call from 0600 GMT that will include third-quarter guidance. TSMC has already flagged a rise in second-quarter revenue of 38.6%. Any profit result above T$374.68 billion would mark the company's highest-ever quarterly net income and its sixth consecutive quarter of profit growth. It remains unclear just how much U.S. President Donald Trump's tariffs will affect TSMC. Taiwan was threatened with a 32% reciprocal tariff rate in April but has yet to be notified of an updated figure that some countries have received. Trump also said this month that tariffs on semiconductors are likely to come soon. The company said in June that U.S. tariffs were having some indirect impact, noting they can lead to slightly higher prices, which may in turn weigh on demand. In March, TSMC announced a $100 billion investment in the U.S. alongside Trump at the White House, on top of $65 billion pledged for three Arizona plants - two of which have been built. Another key issue is the Taiwan dollar's 12% appreciation against the greenback so far this year. TSMC has said a 1% appreciation in the Taiwan dollar typically reduces its gross margin by 0.4 percentage points. In June, the company said that strengthening in the Taiwan dollar had shaved more than 3 percentage points off its gross margin. Shares in TSMC surged some 80% last year but have climbed just 5% for the year to date on worries about tariffs and unfavourable currency exchange rates.
